<?xml version="1.0" encoding="UTF-8"?>
<ref id="B58-pharmaceuticals-13-00464">
 <label>58.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zibara</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Awada</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Dib</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>El-Saghir</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Al-Ghadban</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ibrik</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>El-Zein</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>El-Sabban</surname>
    <given-names>M.</given-names>
   </name>
  </person-group>
  <article-title>Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo</article-title>
  <source>Sci. Rep.</source>
  <year>2015</year>
  <volume>5</volume>
  <fpage>12598</fpage>
  <pub-id pub-id-type="doi">10.1038/srep12598</pub-id>
  <pub-id pub-id-type="pmid">26218768</pub-id>
 </element-citation>
</ref>
